Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
· Issued by Pharvaris N.v.
- Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p
